PPI
Proton pump inhibitor
- Irreversibly blocks the gastric H⁺/K⁺-ATPase → profound acid suppression
- Heals ulcers and erosive esophagitis
- New pumps must be made to recover
- Raised pH reduces absorption of acid-dependent drugs
- Long-term B12/magnesium concerns
- Irreversibly blocks gastric acid secretion
- Reduced absorption of drugs needing an acid environment
- Long-term: B12 deficiency, hypomagnesemia, fracture risk
Drugs with this mechanism (6)
- Dexlansoprazole — Dual-release proton-pump inhibitor.
- Esomeprazole — The S-isomer of omeprazole; a widely marketed proton-pump inhibitor.
- Lansoprazole — PPI with an orally disintegrating option; useful for swallowing difficulty or tube delivery.
- Omeprazole — OTC proton-pump inhibitor; clinically important CYP2C19 inhibition distinguishes it.
- Pantoprazole — A proton-pump inhibitor with few drug interactions; IV available.
- Rabeprazole — PPI least dependent on CYP2C19; genotype and inhibitor effects are comparatively small.
All mechanisms · Open Proton pump inhibitor (PPI) in the interactive console ↗